Erytech Pharma

Thomas Cortese

Yann Godfrin

Fabien Gay

Vanessa Bourgeaux

The invention relates to a pharmaceutical composition containing a PLP-dependent enzyme and optionally its cofactor, pyridoxal phosphate (PLP), and/or a phosphate or non-phosphate precursor of PLP, its use as a drug, its production method and a therapeutic treatment method related to it. The pharmaceutical composition comprises erythrocytes and a pharmaceutically acceptable vehicle, the erythrocytes encapsulating the PLP-dependent enzyme. The PLP-dependent enzyme may be methioninase, tyrosine phenol-lyase, tyrosine aminotransferase or cystathionine beta-synthase.

Pharmaceutical composition comprising erythrocytes encapsulating a PLP-dependent enzyme and, a non-phosphate PLP precursor

The invention relates to a pharmaceutical kit containing a) an injectable suspension of erythrocytes encapsulating a pyridoxal phosphate (PLP)-dependent enzyme and b) a non-phosphate PLP precursor. The invention further relates to methods of producing component(s) of the kit and to therapeutic treatment methods related to the kit. The PLP-dependent enzyme may be a methioninase, a tyrosine phenol-lyase, a tyrosine aminotransferase or a cystathionine beta-synthase.

Growing community of inventors

Labege, France

Thomas Cortese